Standalone Aster revenues grew ~22% YoY to 1311 crore aided by ~10% growth in Average Revenue Per Patient (IP) to 130352 and 16% growth in the total patient volumes. Occupancies improved by 350 bps YoY to 62% led by higher IP volume growth. EBITDA grew ~27% YoY to 264 crore, driven by operating leverage and disciplined cost management. Margins stood at ~20% (up 93 bps YoY). Combined entity Q1FY27 numbers are presented on a pro forma basis, as the merger became effective only on July 1, 2026. Combined revenues grew 20% YoY to 2,597 crore, EBITDA increased 30% YoY to 576...